UKPOL.CO.UK

Category: Speeches

  • Jim Shannon – 2016 Parliamentary Question to the Foreign and Commonwealth Office

    Jim Shannon – 2016 Parliamentary Question to the Foreign and Commonwealth Office

    The below Parliamentary question was asked by Jim Shannon on 2016-05-24.

    To ask the Secretary of State for Foreign and Commonwealth Affairs, what steps the Government is taking to promote pluralism and religious freedom in Syria.

    Mr Tobias Ellwood

    United Nations Security Council Resolution 2254, which we supported, urges all parties to the UN-facilitated political process to adhere to the principle identified by the International Syria Support Group (ISSG) to protect the rights of all Syrians, regardless of ethnicity or religious denomination. Through our membership of the ISSG we will focus all our efforts on ensuring that Syrian minorities are included and safeguarded as the political process progresses. In our contact with members of the Syrian opposition who have signed up to the Geneva Communiqué, we have maintained a strong line on our commitment to pluralism, and the need to ensure that Freedom of Religion or Belief is enshrined as a constitutional right. A proportion of the High Negotiations Council, including members of the negotiating team, are drawn from religious minority groups in Syria’s richly diverse population. We are also supporting non-governmental efforts to promote dialogue between different ethnic and sectarian groups and education on tolerance, integration and pluralism.

  • Ronnie Cowan – 2016 Parliamentary Question to the Department for Work and Pensions

    Ronnie Cowan – 2016 Parliamentary Question to the Department for Work and Pensions

    The below Parliamentary question was asked by Ronnie Cowan on 2016-07-12.

    To ask the Secretary of State for Work and Pensions, if he will make it his policy to ensure that his Department undertakes research into the potential merits of a universal basic income.

    Damian Hinds

    We have no current plans to conduct research on this topic.

  • James Davies – 2016 Parliamentary Question to the Department of Health

    James Davies – 2016 Parliamentary Question to the Department of Health

    The below Parliamentary question was asked by James Davies on 2016-10-07.

    To ask the Secretary of State for Health, what progress his Department has made on increasing the ability of GP practices in North Wales to attract locums since the Government responded to the Third Report of the Welsh Affairs Committee of Session 2014-15, HC 404, on Cross-border health arrangements between England and Wales.

    David Mowat

    The ability of general practitioner practices in North Wales to attract locums is a matter for the Welsh Government, since health and health services are devolved subjects.

  • Liz McInnes – 2015 Parliamentary Question to the Department for Communities and Local Government

    Liz McInnes – 2015 Parliamentary Question to the Department for Communities and Local Government

    The below Parliamentary question was asked by Liz McInnes on 2015-11-17.

    To ask the Secretary of State for Communities and Local Government, what the change in the number of firefighter posts was in Hertfordshire Fire and Rescue Service in 2013-14.

    Greg Clark

    I refer the hon. Member to the answer I gave her on 6 November 2015, PQ 13946.

  • Andrew Percy – 2015 Parliamentary Question to the Department of Health

    Andrew Percy – 2015 Parliamentary Question to the Department of Health

    The below Parliamentary question was asked by Andrew Percy on 2015-12-15.

    To ask the Secretary of State for Health, what steps he is taking to make a cheaper, more effective vaccine against pneumococcal meningitis available on the NHS.

    Jane Ellison

    The availability and pricing of vaccines, including any targeting pneumococcal meningitis, are primarily matters for vaccine manufacturers. Available vaccines, and those close to being licensed, are considered and assessed by the Joint Committee on Vaccination and Immunisation, which advises the Department of Health, on their potential use in the national immunisation programme. Vaccines used in the national immunisation programme are chosen following stringent procurement processes, which include competitive tendering, in order to achieve best value for money.

  • Lord Alton of Liverpool – 2016 Parliamentary Question to the Department of Health

    Lord Alton of Liverpool – 2016 Parliamentary Question to the Department of Health

    The below Parliamentary question was asked by Lord Alton of Liverpool on 2016-01-26.

    To ask Her Majesty’s Government what assessment the Human Fertilisation and Embryology Authority (HFEA) has made of recent research suggesting that the eggs of older women can be rejuvenated through injections of mitochondria from other cells; what data collected from clinics the HFEA holds regarding the incidence of aneuploidy in oocytes over time, and what evidence it has received from (1) OvaScience, (2) Professor Simon Fishel, and (3) other sources, that mitochondrial defects are primarily responsible for age-related exponential increases in oocyte aneuploidy; what published randomised trials the HFEA has been made aware of regarding the Augment technique, and what assessment it has made of those trials; and what assessment the HFEA has made of the credibility of claims by OvaScience and those previously made by Clonaid, in the light of data available in peer-reviewed journals.

    Lord Prior of Brampton

    The Human Fertilisation and Embryology Authority (HFEA) advises that it does not hold data from clinics on the incidence of aneuploidy in oocytes over time, nor has it received evidence from OvaScience, Professor Simon Fishel or other sources that mitochondrial defects are primarily responsible for age-related increases in oocyte chromosomal aneuploidy.

    The HFEA also advises that it has not been made aware of any published randomised trials regarding the Augment technique and has not made an assessment of the credibility of claims by OvaScience and those previously made by Clonaid, in the light of data available in peer-reviewed journals. It is currently considering whether techniques, which involve addition of autologous mitochondria to eggs, would be legal in the United Kingdom (under the framework of the Human Fertilisation and Embryology Act 1990, as amended). Part of this consideration involves considering the claims made for Augment by Ovascience.

    The HFEA has not received any formal applications for clinical use of the Augment technique, and has not made an assessment of the ruling by the US Food and Drugs Administration to which the Noble Lord refers.

  • Lord Alton of Liverpool – 2016 Parliamentary Question to the Department of Health

    Lord Alton of Liverpool – 2016 Parliamentary Question to the Department of Health

    The below Parliamentary question was asked by Lord Alton of Liverpool on 2016-02-23.

    To ask Her Majesty’s Government, further to the Written Answers by Lord Prior of Brampton on 11 February (HL5909, HL5910 and HL5960) and 12 February (HL5909), what specific licence conditions have been required by the Human Fertilisation and Embryology Authority (HFEA) in accordance with its Code of Practice in order to resolve any potential or perceived conflict between the demand for sufficient numbers of zygotes to perform genome editing successfully and the usual practice of transferring embryos to the uterus following assessment of their potential to develop further after at least two to three days; what reasons the person responsible provided when requesting that reference to surplus embryos should be removed from the research project title; and whether they will now place in the Library of the House copies of the patient information and consent forms submitted to the HFEA by the person responsible in order to perform genome editing in human embryos by means of CRISPR-Cas9.

    Lord Prior of Brampton

    The Human Fertilisation and Embryology Authority (HFEA) publishes on its website the inspection report relating to a licence renewal application and the minutes of the Licence Committee’s decision. It does not publish other information associated with a licence application.

    The Licence Committee considering the application to which the noble Lord refers was satisfied that the requirements of General Directions 0008 were met, with the exception of evidence of ethics approval, which must be submitted to the HFEA before any licensed research can begin.

    The HFEA has advised that licence conditions R18-R27 and T97 address any potential conflict between the use of embryos in research and the use of embryos in the provision of treatment services. The person responsible did not give a reason on the application form for requesting that reference to surplus embryos should be removed from the research project title, nor are they required to do so. The removal of ‘surplus’ from the title does not reflect a change in the way embryos will be donated to the research.

  • Rushanara Ali – 2016 Parliamentary Question to the Department for Education

    Rushanara Ali – 2016 Parliamentary Question to the Department for Education

    The below Parliamentary question was asked by Rushanara Ali on 2016-03-10.

    To ask the Secretary of State for Education, if she will make it her policy to make the entitlement to an early education place a legal requirement.

    Mr Sam Gyimah

    English local authorities have a statutory duty under section 7 of the Childcare Act 2006 to secure a free early education place of 15 hours a week for 38 weeks of the year for all three- and four-year-olds and two-year-olds who meet the eligibility criteria. The early education entitlement is not a legal requirement for parents, and we know that the current model is extremely successful, with 99% of four-year-olds and 94% of three-year-olds taking up a place. And, Based on survey data collected from local authorities in the autumn of 2015 it is estimated that 182,000 two-year-olds – around 72% of eligible children – have taken up a place on the two-year-old programme.

    The Secretary of State has a statutory duty under the Childcare Act 2016 to secure an additional 15 hours a week of free childcare for 38 weeks of the year for working parents of three- and four-year-olds.

    The Secretary of State will discharge the duty in clause 2 of the Childcare Act, the duty to secure 30 hours of free childcare for working parents, through all local authorities in England. Local authorities will, therefore, be required to secure childcare provision free of charge to qualifying children.

  • Louise Haigh – 2016 Parliamentary Question to the Department for Business, Innovation and Skills

    Louise Haigh – 2016 Parliamentary Question to the Department for Business, Innovation and Skills

    The below Parliamentary question was asked by Louise Haigh on 2016-04-15.

    To ask the Secretary of State for Business, Innovation and Skills, how many civil servants were employed in each location at the UK Space Agency in the last year for which figures are available.

    Joseph Johnson

    The number of civil servants employed by the UK Space Agency is shown in the attached table and represents the position as at 31 December 2015. The Department does not hold centrally any location data for its agencies prior to this date.

  • Ian Austin – 2016 Parliamentary Question to the Department of Health

    Ian Austin – 2016 Parliamentary Question to the Department of Health

    The below Parliamentary question was asked by Ian Austin on 2016-05-24.

    To ask the Secretary of State for Health, if he will make it his policy to continue supplying Orkambi to cystic fibrosis patients currently receiving that drug as part of a clinical trial in the event of that drug not being approved for NHS use by the NICE.

    George Freeman

    The National Institute for Health and Care Excellence is currently appraising Orkambi (lumacaftor-ivacaftor) for the treatment of cystic fibrosis homozygous for the F508del mutation.

    NHS England has advised that it has published policies that cover the different circumstances where a patient is on a clinical trial and where the drug is not subsequently approved for National Health Service use. In the circumstances of a commercially funded trial it is normally the responsibility of the manufacturer or the hospital to consider whether they wish to continue making it available to individual patients.